China approves Dupixent® for COPD treatment, following EU approval and Phase 3 trials.

China has approved Dupixent® (dupilumab) as the first biologic treatment for chronic obstructive pulmonary disease (COPD) with elevated blood eosinophils. This follows its approval in the EU and is supported by Phase 3 trials showing significant benefits in reducing exacerbations and improving lung function and quality of life. As COPD is highly prevalent in China, this approval aligns with the nation's Healthy China 2030 public health initiative.

September 27, 2024
27 Articles

Further Reading